Načítá se...
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
Human epidermal growth factor receptor (HER)2 over-expression is associated with a shortened disease-free interval and poor survival. Although the addition of trastuzumab to chemotherapy in the first-line setting has improved response rates, progression-free survival, and overall survival, response...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2750101/ https://ncbi.nlm.nih.gov/pubmed/19664181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2324 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|